ACET vs. IVA, TELO, SKYE, GLSI, GOSS, SCPH, OMER, PRQR, AEON, and VERU
Should you be buying Adicet Bio stock or one of its competitors? The main competitors of Adicet Bio include Inventiva (IVA), Telomir Pharmaceuticals (TELO), Skye Bioscience (SKYE), Greenwich LifeSciences (GLSI), Gossamer Bio (GOSS), scPharmaceuticals (SCPH), Omeros (OMER), ProQR Therapeutics (PRQR), AEON Biopharma (AEON), and Veru (VERU). These companies are all part of the "pharmaceutical preparations" industry.
Inventiva (NASDAQ:IVA) and Adicet Bio (NASDAQ:ACET) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.
Adicet Bio's return on equity of 0.00% beat Inventiva's return on equity.
Inventiva presently has a consensus price target of $17.00, indicating a potential upside of 432.92%. Adicet Bio has a consensus price target of $12.83, indicating a potential upside of 749.89%. Given Inventiva's higher possible upside, analysts plainly believe Adicet Bio is more favorable than Inventiva.
In the previous week, Inventiva and Inventiva both had 3 articles in the media. Adicet Bio's average media sentiment score of 0.35 beat Inventiva's score of 0.00 indicating that Inventiva is being referred to more favorably in the media.
Inventiva has higher earnings, but lower revenue than Adicet Bio.
Adicet Bio received 270 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 59.09% of users gave Adicet Bio an outperform vote.
Inventiva has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.
19.1% of Inventiva shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 29.5% of Adicet Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Inventiva beats Adicet Bio on 9 of the 14 factors compared between the two stocks.
Get Adicet Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adicet Bio Competitors List
Related Companies and Tools
